Lionco Pharmaceutical Group Co.,Ltd.

Shanghai Stock Exchange 603669.SS

Lionco Pharmaceutical Group Co.,Ltd. Price to Book Ratio (P/B) on January 14, 2025: 4.25

Lionco Pharmaceutical Group Co.,Ltd. Price to Book Ratio (P/B) is 4.25 on January 14, 2025, a 0.84% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Lionco Pharmaceutical Group Co.,Ltd. 52-week high Price to Book Ratio (P/B) is 6.57 on December 09, 2024, which is 54.40% above the current Price to Book Ratio (P/B).
Lionco Pharmaceutical Group Co.,Ltd. 52-week low Price to Book Ratio (P/B) is 2.50 on February 07, 2024, which is -41.23% below the current Price to Book Ratio (P/B).
Lionco Pharmaceutical Group Co.,Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 3.71.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 603669.SS

Lionco Pharmaceutical Group Co.,Ltd.

CEO	Ms. Ling Ping Tao
IPO Date	May 28, 2015
Location	China
Headquarters	Commercial and Residential Building 2
Employees	475
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular, detoxification, anti-tumor, and other products. It also operates research institutes that specialize in the research of chemical drugs, natural medicines, and biological drugs. Lionco Pharmaceutical Group Co., Ltd. was founded in 2003 and is based in Shannan, China.

Key trends

Past 5 years